Beta spoločnosti Aerie Pharmaceuticals Inc
Aká je hodnota metriky Beta spoločnosti Aerie Pharmaceuticals Inc?
Hodnota metriky Beta spoločnosti Aerie Pharmaceuticals Inc je 0.00
Aká je definícia metriky Beta?
BETA koeficient vyjadruje či je akcia volatilnejšia ako celkový trh. Beta nižšie ako 1 značí, že akcia je menej volatilná ako trh a beta vyššie ako 1 značí, že akcia je volatilnejšia. Volatilita sa miera pomocou kolísavosti ceny akcie.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Aerie Pharmaceuticals Inc
Čomu sa venuje spoločnosť Aerie Pharmaceuticals Inc?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Firmy s metrikou beta podobnou spoločnosti Aerie Pharmaceuticals Inc
- Hodnota metriky Beta spoločnosti Vision Marine Technologies je 0.00
- Hodnota metriky Beta spoločnosti Ely Gold Royalties je 0.00
- Hodnota metriky Beta spoločnosti Glacier Lake Resources je 0.00
- Hodnota metriky Beta spoločnosti Magnum Mining and Exploration je 0.00
- Hodnota metriky Beta spoločnosti Africa Opportunity Fund je 0.00
- Hodnota metriky Beta spoločnosti Fulcrum Utility Services je 0.00
- Hodnota metriky Beta spoločnosti Aerie Pharmaceuticals Inc je 0.00
- Hodnota metriky Beta spoločnosti Gullewa je 0.00
- Hodnota metriky Beta spoločnosti S.A.L. Steel je 0.00
- Hodnota metriky Beta spoločnosti Andina Acquisition III je 0.00
- Hodnota metriky Beta spoločnosti Andina Acquisition III je 0.00
- Hodnota metriky Beta spoločnosti Brilliant Acquisition je 0.00
- Hodnota metriky Beta spoločnosti Indokem je 0.00